Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Alector (NASDAQ:ALEC) and Milestone Pharmaceuticals (NASDAQ:MIST) Critical Review
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Alector, Inc. (NASDAQ:ALEC) Given Average Rating of “Reduce” by Analysts
Short Interest in Alector, Inc. (NASDAQ:ALEC) Expands By 35.9%
Alector (NASDAQ:ALEC) Trading 4.8% Higher – Here’s Why
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Alector to Participate in the Bank of America CNS Therapeutics Conference
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
Alector shares plunge after dementia drug fails to slow disease progression
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Alector, Inc. - Special Call
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Alector to Participate in Upcoming Healthcare Conferences
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
Alector (ALEC) Q2 Revenue Falls 48%
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Alector Provides Executive Leadership Update
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Alector to Participate in Upcoming Healthcare Conferences
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
Alector Provides Executive Leadership Update
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates